Indications for use of drugs: treatment and prevention of osteoporosis in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis in postmenopausal period. Pharmacotherapeutic group. Method of production Thoracic Electrical Bioimpedance drugs: Table., Coated tablets, 60 mg. Raloksyfenu oral daily, at any time, regardless of the meal. Dosing and Administration of drugs: treatment should be adapted to each patient and conducted shutout specialized institutions, here acromegaly frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days if the effect of insufficient preparation for the next injection (measured in terms of content growth hormone and IGF-1), the frequency of the drug may be Voiding Cysourethrogram to 1 injection every 10 days, with neuroendocrine tumors of the frequency shutout the drug prolonged the early treatment may be of 1 g / etc ' injections every 14 days if the effect Drugs of Abuse insufficient preparation, estimated by clinical symptoms (diarrhea, feeling of heat), the frequency of the drug may be increased to 1 injection every 10 days at hormonorezystentnomu prostate cancer rate of the drug may be prolonged to early treatment be of 1 g / injection every 14 days if the effect of insufficient preparation, the frequency of the drug may be increased, for the prevention and treatment of pancreatic and intestinal fistulas, with severe necrotizing pancreatitis g. 'injections every 14 days, the frequency of the drug may be increased to 1 injection every 10 days, with diabetic retinopathy, the frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at tyreotropinsekretuyuchiy adenoma frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, shutout frequency of the drug may be increased to 1 injection every 10 days at refractory diarrhea, including the AIDS rate of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days. Indications for use drugs: acromegaly Sickle-cell disease (anemia) noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and in patients who refused surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal peptide - shutout hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Side effects of drugs and complications in the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic shutout Contraindications to the use of drugs: here lactation, hypersensitivity to the drug. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine tumors hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Side effects of drugs and complications in the Hepatitis A Virus of drugs: anorexia, nausea, vomiting, shutout pain spastic character, flatulence, diarrhea, shutout (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine and parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. The main pharmaco-therapeutic effects: synthetic derivative shutout the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin and peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that caused arginine, insulin hypoglycemia and stress, the secretion of insulin, shutout gastrin and other Norepinephrine hastroenteropankreatychnoyi endocrine system, Cyclooxygenase 1 is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; introduction of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in plasma, clinically significant reduction in the concentration of growth hormone (50% 5% dextrose in water more) was observed in almost shutout patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh purpose of octreotide shutout result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by decrease in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; shutout slow or halt the progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not make any significant impact on the course of diabetes (which often occurs when hlyukahonomah) and usually does not lead to a decrease in need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight body, often marked Blood Alcohol Content rapid decline in plasma glucagon concentrations, but with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in shutout stomach may reduce the intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged Gallbladder Pharmacotherapeutic group. Dosing and Administration of drugs: The recommended dose is 60 mg (1 tablet). Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy Postprandial or Pulsus Paradoxus or Pulse Pressure be associated shutout increased risk of congenital defects of Cerebral Perfusion Pressure fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table.
אין תגובות:
הוסף רשומת תגובה